Pre-made Bimekizumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bimekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody[2] that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis.
| Products Name (INN Index) | Pre-Made Bimekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody |
|---|---|
| INN Name | Bimekizumab |
| Target | IL17A |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | UCB |
| Conditions Approved | Plaque psoriasis |
| Conditions Active | Ankylosing spondylitis,Psoriatic arthritis,Hidradenitis suppurativa,Ulcerative colitis,Axial spondylarthritis |
| Conditions Discontinued | Psoriasis,Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL17A/IL17 |
| Package |
